Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
  • C07K16/241—Tumor Necrosis Factors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P21/00—Preparation of peptides or proteins
  • C12P21/005—Glycopeptides, glycoproteins
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
  • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Definitions

• the present invention relates to an improved process to obtain substantial amount of monoclonal antibodies with desired profile of charged variants.
• the process also provides an antibody with desired profile of glycans.
• the process involves initially culturing the mammalian cells at a suitable temperature and subsequently reducing the temperature and optionally by simultaneous addition of suitable amino acid(s) during production of the desired molecule.
• Proteins are large and complex molecules. They are required to be in their native confirmation in order to remain biologically active. Further, at high concentration, protein molecules in solution are susceptible to undergo aggregation or degradation or certain modifications with time during storage.
• the present invention provides an improved method to obtain increased amount of desired quality product, preferably, monoclonal antibody.
• Monoclonal antibodies mAbs
• mAbs Monoclonal antibodies
• Monoclonal antibodies like many other proteins have charge heterogeneity which optimize electrostatic interactions and regulates their structure, stability, chemical and biological properties.
• various forms of micro heterogeneity occur due to degradation, modification or various enzymatic rocesses.
• Degradation of protein takes place due to chemical instability or physical instability. Chemical instability majorly can be result of deamidation, racemization, hydrolysis, oxidation, beta elimination or disulfide exchange. Chemical instability results in the formation of various charge variants and thus modifying the properties of the biomolecules. Chemical modification such as deamidation and sialylation, respectively, result in the increase in the net negative charge on mAbs and causes a decrease in pi values.
• Other mechanisms of generation of acidic variants are known in the prior art. Deamidated isoforms are susceptible to degrade with the loss of activity and therefore, it impacts significantly activity as well as stability of monoclonal antibody proteins.
• Fc glycans may contain several different types of terminal sugars that affect functions of antibodies. Effect of terminal galactosylation is known to the skilled person. Galactosylation pattern of different immunoglobulins shows product-specific variability in such immunoglobulins. It is important to note that variation in the terminal galactosylation affects the antibody binding to antigen and does influence greatly the CDC activity of the molecule. On the other hand, varying degree of galactosylation is known to have less influence on ADCC activity, whereas afucosylation is extremely important for ADCC activity.
• US 5705364 discloses cell culture processes for controlling the amount of sialic acid present on an oligosaccharide side chain of a glycoprotein by adding an alkanoic acid or a salt thereof to the culture at a concentration of about 0.1 mM to about 20 mM maintaining the osmolality of the culture at about 250 to about 600 mOsm and maintaining the temperature of the culture at a temperature about between 30 °C and 35 °C.
• US 5976833 provide a method for improving productivity in the production of useful substances by animal cells. It discloses a method for animal cell culture to produce a desired substance, comprising the steps of (1) culturing animal cells at a temperature at which the animal cells can grow; and (2) culturing the animal cells at a lower temperature.
• WO 2014035475 discloses a method for controlling the oligosaccharide distribution of a recombinantly- expressed protein comprising supplementing a cell culture media used in the recombinant expression of said protein with a yeast hydrolysate supplement and a plant hydrolysate supplement. It also discloses method for controlling the oligosaccharide distribution of an antibody by modulating asparagine amino acid concentration of the cell culture media; whereas the present invention does not involve supplementation of such hydrolysate in the culture media.
• the present invention provides such an improved process of the monoclonal antibody production using modified' cell culture method.
• the process according to the present invention does not include either addition of salt or maintenance of suitable osmolality.
• the present invention provides novel method for the production of monoclonal antibodies with desired profile of glycans and charged variants.
• the present invention provides an improved process to obtain substantial amount of monoclonal antibodies with desired profile of glycans and charged variants using modified cell culture method.
• cell culture method is characterized by maintaining the cell culture production condition at various temperatures either at once or in a step-wise manner during the cell culture process.
• the present invention provides an improved process for the production of monoclonal antibody by carrying out the production process at an initial higher temperature in the growth phase and subsequently reducing the temperature of the culture system to a second lower temperature either during the mid-log to late-log phase or the stationary phase.
• the present invention provides art improved process for the production of monoclonal antibody by feeding suitable amino acids to the culture system during the mid-log to late-log phase or the stationary phase.
• amino acid(s) are added to the cell culture medium at certain concentrations and at specific time- intervals during cell culture process.
• amino acids are selected from glutamine and asparagine or combinations, thereof.
• the present invention provides an improved upstream process to obtain substantial amount of monoclonal antibodies with desired profile of glycans and charged variants by carrying out the process at an initial higher temperature in the growth phase, and subsequently, reducing the temperature of the culture system to a second lower than the initial temperature either during the mid-log to late-log phase or at the stationary phase with simultaneous feeding of amino acid(s) to the culture media.
• the amino acid according to the present invention is selected from amide group containing and basic amino acids e.g. glutamine, asparagine, histidine, lysine, arginine and a combination thereof.
• the monoclonal antibodies are selected from anti- HER antibody, anti-TNF antibody, anti-VEGF antibody and anti-CD20 antibody.
• the monoclonal antibodies are selected from trastuzumab, pertuzumab, infliximab, adalimumab, bevacizumab, ranibizumab and rituximab.
• Figure 1 Illustrates the charged variants profile of the purified Adalimumab protein by HP-IEC.
• Figure 2 Illustrates the glycans profile of the purified Adalimumab protein by
• the present invention provides process for the production of monoclonal antibody with desired profile of charged variants while maintaining the a desired glycan profile of the protein by carrying out the production process at an initial higher temperature in the growth phase, and subsequently, decreasing the temperature of ihe culture system to a lower temperature at once or in a step-wise manner, either during the mid-log to late-log phase or at the stationary phase.
• cell culture method is characterized by maintaining the cell culture production condition at various temperatures either at once or in a stepwise manner during the cell culture process.
• the present invention provides a process for the production of substantial amount of monoclonal antibody with desired profile of glycans preferably by feeding suitable amino acids such as amide group containing amino acid(s) and/or basic amino acid(s) to the culture system.
• suitable amino acids such as amide group containing amino acid(s) and/or basic amino acid(s)
• amino acid(s) can be fed at any stage during the mid-log phase to the stationary phase.
• amino acid(s) are added to the cell culture medium at certain concentrations and at specific time- intervals during celI culture process.
• addition of amino acid(s) is performed at least at two different intervals during the cell culture process.
• addition of amino acid(s) to the cell culture medium is performed at concentration less than 20mM, preferably less than 10 mM each time.
• the present invention provides substantial amount of monoclonal antibodies with desired profile of glycans and charged variants by carrying out the production process at an initial higher temperature in the growth phase, and subsequently, decreasing the temperature of the culture system to a second lower temperature either during the mid-log to late-log phase or at the stationary phase and feeding of amino acid(s) to the culture system.
• the amino acid according to the present invention is selected from amide group containing and basic amino acids e.g. glutamine, asparagine, histidine, lysine, arginine and a combination thereof.
• the initial higher temperature of the culture system is maintained at 37°C.
• the temperature of the. culture system according to the present invention can be decreased up to 30 °C either at once or step-wise at specific time interval, at any stage during the mid-log phase to stationary phase.
• the process according to the present invention provides substantial amount of monoclonal antibodies with desired profile of glycans and charged variants. Furthermore, the process maintains the desired glycans profile of the monoclonal antibody.
• the present invention provides desired glycans profile of the protein, preferably, monoclonal antibody by feeding suitable amino acids such as glutamine and/or asparagine to the culture system at any stage during the mid- log phase to stationary phase.
• suitable amino acids such as glutamine and/or asparagine
• the amount of amino acid(s) added is in the range of 1 to 4 mM, preferably 2 to 3 mM. Feeding of glutamine and/or asparagine according to the present invention to the cell culture media during production was found to augment the formation of the desired glycan(s) moiety (ies) in product-specific manner in monoclonal antibody protein structure.
• the present invention provides production of substantial amount of monoclonal antibody with desired profile of glycans and charged variants by carrying out the process at an initial higher temperature in the growth phase, and subsequently, decreasing the temperature of the culture system to a second lower temperature either during the mid-log to late-log phase or at the stationary phase and by addition of suitable amino acid(s) (glutamine and/or asparagine) during production of the desired protein.
• suitable amino acid(s) glutamine and/or asparagine
• the present invention provides a process for the production of antibody with desired profile of glycans and charged variants where glucose concentration is maintained in the range of 0.5 g/L to 8 g/L, preferably 2 g/L to 4 g/L, more preferably about 2.5 g/L.
• the present invention provides a process for the production of antibody with desired profile of glycans and charged variants where pH is maintained during production in the range of pH 6 to pH 7.5 by using suitable buffer selected from sodium bicarbonate, sodium carbonate and HEPES buffer.
• the present invention provides a process for the production of antibody with desired profile of glycans and charged variants where cell productivity is maintained not less than 0.5 g/L. preferably 1 - 4 g/L.
• the present invention provides a process for the production of antibody with desired profile of glycans and charged variants where cell viability is maintained not less than 30 %, preferably about 80%, more preferably greater than 95%.
• the monoclonal antibodies are selected from trastuzumab, pertuzumab, infliximab, adalimumab, bevacizumab, ranibizumab and rituximab.
• Glycan- refers to a polysaccharide or oligosaccharide. Glycans can be homo- or heteropolymers of monosaccharide residues, and can be linear or branched. Glycan may also be used to refer to the carbohydrate portion of a glycoconjugate, such as a glycoprotein, glycolipid, or a proteoglycan.
• Mid-log phase It is defined as the growth phase of cells in a culture medium during which cell population increases exponentially. This phase is represented by a part of the growth curve, which appears as a straight line segment when the logarithmic values of the cell population are plotted against time, called as logarithmic phase, and the mid-point of which is called as the mid-log phase.
• Late-log phase- It is defined as the growth phase of cells at the late-log phase prior to the transition to the stationary phase. This phase is represented by a part of the growth curve, which appears as a straight line segment when the logarithmic values of the cell population are plotted against time, called as logarithmic phase- and the end phase of which is called as the late-log phase.
• High Pressure Ion Exchange Chromatography Separation of different charged variants of the purified monoclonal antibody e.g. Adalimumab is performed by using an analytical HP-weak cation exchange chromatography. The column is equilibrated in sodium phosphate buffer of pH 6.9 (mobile phase A). Elution of the charged species variants of the said protein is carried ou.t with increasing salt concentration (sodium chloride) in mobile phase A at 0.5 mL/min.
• Capillary Electrophoresis-Laser Induced Fluorescence CE-LIF: Glycan analysis (glycosylation variants) of the purified monoclonal antibody preparation, e.g.
• Adalimumab is conducted by CE-LIF method after isolating the carbohydrate moieties from the said protein by PNGase treatment. Following the enzymatic treatment, the carbohydrate (glycans) moieties are labeled by APTS (8-aminopyrene 1,2,6- trisulfonate) and the derivatized glycans are then separated by the capillary system (N- CHO coated; 50 cm x 50 ⁇ m) on the basis of the hydrodynamic size. Glycans are identified against labeled glucose ladder standard detected by a LIF detector with an excitation wavelength of 488 nm and an emission wavelength of 520 nm.
• Mammalian cells expressing anti-TNFa antibody adalimumab were generated by standard molecular biology techniques. Clones were subjected to limiting dilution to obtain a single cell derived homogenous population. The cells were cryopreserved in the form of cell banks and used for further development. Cells were revived and propagated with a series of inoculum development steps and inoculated in the bioreactor containing suitable growth media. Cell culture was performed in a controlled environment by maintaining pH 7.2 ⁇ 0.4 using CO 2 gas and /or sodium bicarbonate, as and when required. The dissolved oxygen concentration was maintained at 40 ⁇ 20% saturation with sparging of air and/or oxygen gas and by controlling agitation speed in the bioreactor. Temperature was controlled at 37 oC. Growth media contains following components:
• the experiment was carried out in a 30L bioreactor.
• the growth conditions were identical to example-1 including the common feed media and other process parameters except that of the temperature conditions of the culture system.
• the temperature of the culture system was decreased from 37 oC to 35 oC at the late log phase.
• Adalimumab was purified up to satisfactory level and submitted to HP-IEC and CE-LIF analysis for charged species variants and glycans profile, respectively, as shown in Table 1 and Table 2.
• the experiment was carried out in a 30L bioreactor.
• the growth conditions were identical to example- 1 including the common feed media and other process parameters except that of the feeding of glutamine amino acids to the culture system.
• the feeding of 2 mM glutamine was started at the mid-log-phase of cell growth and was continued till the end of production at specific intervals.
• Adalimumab was purified up to satisfactory level and submitted to HP-IEC and CE-LIF analysis for charged species variants and glycans profile, respectively, as shown in Table 1 and Table 2.
• the experiment was carried out in a 30L bioreactor.
• the growth conditions were identical to example-1 including the common feed media and other process parameters except that of the temperature condition and feeding of glutamine to the culture system.
• Temperature of the culture system was decreased from 37 oC to 35oC at the mid log phase, after which time temperature of the culture system was further decreased to 33 oC during the transition from log-phase to stationary phase.
• Feeding of 3 mM glutamine was started at the mid-log phase and was continued at specific intervals till the end of production of the desired monoclonal antibody.
• Adalimumab was purified up to satisfactory level and submitted to HP-IEC and CE-LIF analysis for charged species variants and glycans profile, respectively, as shown in Table 1 and Table 2.
• Trastuzumab was purified up to satisfactory level and submitted to HP-IEC and CE-LIF analysis for charged species variants and glycans profile, respectively, as shown in Table 1 and Table 2.
• the experiment was carried out in a bioreactor.
• the growth conditions were identical to example- 1 including the common feed media and other process parameters except that of the temperature condition and feeding of glutamine to the culture system.
• Temperature of the culture system was decreased from 37 oC to 33'C during the transition from log-phase to stationary phase.
• Feeding of 2 mM glutamine was started at the mid-log phase and was continued at specific intervals till the end of production of the desired monoclonal antibody.
• the experiment was carried out in a 30L bioreactor (culti-flask).
• the growth conditions were identical to example-1 including the common feed media and other process parameters except that of the temperature condition and feeding of glutamine to the culture system.
• Temperature of the culture system was decreased from 37 oC to 35oC during the transition from log-phase to stationary phase. No further feeding of glutamine was done other than that in the initial batch media.
• Bevacizumab was purified up to satisfactory level and submitted to HP-IEC and CE-LIF analysis for charged species variants and glycans profile, respectively, as shown in Table 1 and Table 2.
• the experiment was carried out in a bioreactor.
• the growth conditions were identical to example- 1 including the common feed media and other process parameters except that of the temperature condition and feeding of glutamine to the culture system. Temperature of the culture system was maintained at 37 oC during the entire batch. Feeding of 4 mM glutamine was started at the mid-log phase and was continued at specific intervals till the end of production of the desired monoclonal antibody.
• Bevacizumab was purified up to satisfactory level and submitted to HP-IEC and CE-LIF analysis for charged species variants and glycans profile, respectively, as shown in Table 1 and Table 2.
• the experiment was carried out in a bioreactor.
• the growth conditions were identical to example- 1 including the common feed media and other process parameters except that of the temperature condition and feeding of glutamine to the culture system. Temperature of the culture system was maintained at 37 oC during the entire batch. No further feeding of glutamine was done other than that in the initial batch media.
• Rituximab was purified up to satisfactory level and submitted to HP-IEC and CE-LIF analysis for charged species variants and glycans profile, respectively, as shown in Table 1 and Table 2.
• the experiment was carried out in a bioreactor.
• the growth conditions were identical to example- 1 including the common feed media and other process parameters except that of the temperature condition and feeding of glutamine to the culture system. Temperature of the culture system was maintained at 37 oC during the entire batch. Feeding of 4 mM glutamine was started at the mid-log phase and was continued at specific intervals till the end of production of the desired monoclonal antibody.
• Rituximab was purified up to satisfactory level and submitted to HP-IEC and CE-LIF analysis for charged species variants and glycans profile, respectively, as shown in Table I and Table 2.
• the experiment was carried out in a 30L bioreactor (200L bioreactor).
• the growth conditions were identical to example-1 including the common feed media and other process parameters except that of the temperature condition and feeding of glutamine to the culture system.
• Temperature of the culture system was maintained at 37 oC during the entire batch. Feeding of 2 mM glutamine was started at the mid-log phase and was continued at specific intervals til! the end of production of the desired monoclonal antibody.
• Trastuzumab was purified up to satisfactory level and submitted to HP-IEC and CE-LIF analysis for charged species variants and glycans profile, respectively, as shown in Table 1 and Table 2.
• the experiment was carried out in a 30L bioreactor (culti-flask).
• the growth conditions were identical to example- 1 including the common feed media and other process parameters except that of the temperature condition and feeding of glutamine to. the culture system.
• Temperature of the culture system was decreased from 37 oC to 35oC during the transition from log-phase to stationary phase. No further feeding of glutamine was done other than that in the initial batch media.
• Trastuzumab was purified up to satisfactory level and submitted to HP-IEC and CE-LIF analysis for charged species variants and glycans profile, respectively, as shown in Table 1 and Table 2. RESULTS
• the obtained product is subsequently purified and suitably formulated by techniques known in the art.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Medicinal Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oncology (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Microbiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Publications (1)

Family

ID=51794933

Family Applications (1)

Country Status (18)

Cited By (16)

Families Citing this family (3)

Citations (9)

Family Cites Families (1)

• 2014
  • 2014-07-07 HK HK16106205.0A patent/HK1218297A1/zh unknown
  • 2014-07-07 SG SG11201510342VA patent/SG11201510342VA/en unknown
  • 2014-07-07 BR BR112015032800A patent/BR112015032800A2/pt not_active IP Right Cessation
  • 2014-07-07 AR ARP140102519A patent/AR096839A1/es unknown
  • 2014-07-07 IN IN2285MU2013 patent/IN2013MU02285A/en unknown
  • 2014-07-07 US US14/903,093 patent/US20160215319A1/en not_active Abandoned
  • 2014-07-07 CA CA2917484A patent/CA2917484A1/en not_active Abandoned
  • 2014-07-07 MX MX2016000123A patent/MX2016000123A/es unknown
  • 2014-07-07 EP EP14789418.2A patent/EP3019528A1/en not_active Withdrawn
  • 2014-07-07 WO PCT/IN2014/000450 patent/WO2015004679A1/en not_active Ceased
  • 2014-07-07 EA EA201690171A patent/EA201690171A1/ru unknown
  • 2014-07-07 NZ NZ715246A patent/NZ715246A/en not_active IP Right Cessation
  • 2014-07-07 JP JP2016522968A patent/JP2016526385A/ja active Pending
  • 2014-07-07 TW TW103123312A patent/TW201514305A/zh unknown
  • 2014-07-07 AU AU2014288811A patent/AU2014288811B2/en not_active Ceased
  • 2014-07-07 CN CN201480038458.4A patent/CN105431454A/zh active Pending
• 2015
  • 2015-12-21 IL IL243011A patent/IL243011A0/en unknown
  • 2015-12-22 ZA ZA2015/09334A patent/ZA201509334B/en unknown

Patent Citations (9)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events